08:00 , Nov 10, 1997 |  BC Week In Review  |  Company News

Antivirals board of directors update

AntiVirals Inc. (AVII), Portland, Ore.   Business: Cardiovascular, Drug delivery   Appointed: Jeffrey Lillard, managing director of ImmunoTherapy Corp., which AVII plans to acquire (see B2)  ...
08:00 , Nov 10, 1997 |  BC Week In Review  |  Company News

Antivirals, ImmunoTherapy Corp. deal

AVII signed a letter of intent to acquire ImmunoTherapy, a cancer vaccine company, for $24 million in AVII common stock and warrants. ImmunoTherapy is conducting Phase II trials of CTP-37, a synthetic cancer vaccine, to...
08:00 , Nov 10, 1997 |  BC Week In Review  |  Company News

Antivirals management update

AntiVirals Inc. (AVII), Portland, Ore.   Business: Cardiovascular, Drug delivery   Hired: Gordon Duncan as VP of regulatory affairs, formerly a consultant  ...
07:00 , Sep 22, 1997 |  BC Week In Review  |  Company News

Antivirals board of directors update

Antivirals Inc. (AVII), Portland, Ore.   Business: Cardiovascular, Drug discovery, Drug delivery   Appointed: Patrick Iversen, VP of R&D   Retired: Donald Johnson, former president of Technology Conversion Inc.  ...
07:00 , Aug 25, 1997 |  BC Week In Review  |  Company News

Antivirals management update

Antivirals Inc. (AVII), Portland, Ore.   Business: Cardiovascular, Drug delivery   Resigned: James Summerton, founder, president, CSO and director; CEO Denis Burger, Ph.D., will assume the additional position of president, and Alan Timmins, COO and...
07:00 , Aug 18, 1997 |  BC Week In Review  |  Clinical News

Antivirals preclinical data

AVII reported 100 percent efficacy of AVI-2221 versus controls in preventing restenosis in a rat model (p=0.05). Three experiments involving 10-15 rats each were conducted. A 25 percent gel containing the antisense compound was administered...
07:00 , Jun 9, 1997 |  BioCentury  |  Finance

Aware of the overhang

Aware of the overhang The separation of Allergan Ligand Retinoid Therapeutics' (ALRIZ) 3.25 million units shouldn't have a major impact on shares of Ligand Pharmaceuticals (LGND), even though exercise of the warrants could add 6.5...
08:00 , Mar 10, 1997 |  BC Week In Review  |  Company News

Antivirals management update

AntiVirals Inc. , Portland, Ore.   Business: Drug delivery, Cardiopulmonary   Hired: Frederick Pearson III, Ph.D., as VP of regulatory affairs and clinical development; formerly director of biotechnology programs of the Colorado Advanced Technology Institute...
07:00 , Aug 2, 1993 |  BC Week In Review  |  Company News

Quantech deal

QQQQ executed a letter of intent to purchase all the outstanding shares of HybriLogic Corp. in exchange for 600,000 shares of QQQQ. The company said HybriLogic will provide the antibody supply QQQQ needs to develop...